Loading clinical trials...
Loading clinical trials...
An Exploratory Study to Determine Potential Predictive Markers of Response and/or Toxicity in Patients With Unresectable Stage III or IV Malignant Melanoma Randomized and Treated With Ipilimumab (MDX-010/BMS-734016) at Two Dose Levels
The purpose of this study is to identify candidate markers predictive of response and/or serious toxicity to BMS-734016 (MDX-010).
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
Comprehensive Cancer Center
Palm Springs, California, United States
The Angeles Clinic And Research Institution
Santa Monica, California, United States
Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States
Local Institution
Aarhus C, Denmark
Local Institution
Odense C, Denmark
Local Institution
Jerusalem, Israel
Local Institution
Bari, Italy
Local Institution
Forlì, Italy
Local Institution
Ravenna, Italy
Local Institution
Rimini, Italy
Start Date
November 1, 2005
Primary Completion Date
October 1, 2007
Completion Date
October 1, 2007
Last Updated
September 29, 2016
80
ESTIMATED participants
Ipilimumab
DRUG
Ipilimumab
DRUG
Lead Sponsor
Bristol-Myers Squibb
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions